What is the checklist for administering thrombolytic therapy (alteplase) to an adult with acute ischemic stroke?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Thrombolytic Checklist for Acute Ischemic Stroke

Administer IV alteplase 0.9 mg/kg (maximum 90 mg) over 60 minutes with 10% as initial bolus over 1 minute to eligible patients within 4.5 hours of symptom onset or last known well, prioritizing treatment as quickly as possible because every minute of delay worsens outcomes. 1

Time Windows and Eligibility

0-3 Hour Window (Broadest Eligibility)

  • All adults ≥18 years including those >80 years old 1
  • All stroke severities including severe strokes (high NIHSS) 1
  • No upper age limit - benefit proven equally in patients <80 and >80 years 1

3-4.5 Hour Window (Additional Restrictions)

Eligible if patient meets ALL of the following 1:

  • Age ≤80 years
  • NIHSS score ≤25
  • No history of BOTH diabetes AND prior stroke (either alone is acceptable)
  • Not taking oral anticoagulants
  • No imaging evidence of ischemic injury >1/3 MCA territory

Pre-Treatment Requirements

Blood Pressure

  • Must be <185/110 mmHg before starting alteplase 1
  • Can use antihypertensive agents to achieve this target
  • Assess BP stability before initiating treatment
  • Maintain BP <180/105 mmHg for 24 hours post-treatment 1

Blood Glucose

  • Must be >50 mg/dL 1
  • Correct hypoglycemia before treatment

Imaging Requirements

  • CT or MRI must exclude intracranial hemorrhage 1
  • Early ischemic changes of mild-to-moderate extent are acceptable 1
  • Do NOT give if frank hypodensity or extensive clear hypoattenuation present 1
  • Ischemic injury >1/3 MCA territory is a contraindication in the 3-4.5 hour window 1

Medication History Considerations

Antiplatelet Therapy - ACCEPTABLE

  • Single antiplatelet (aspirin or clopidogrel): Give alteplase - benefit outweighs small increased sICH risk 1
  • Dual antiplatelet therapy (aspirin + clopidogrel): Give alteplase - benefit outweighs probable increased sICH risk 1
  • Do NOT give any antiplatelet drugs for 24 hours after alteplase 1

Anticoagulation

  • Oral anticoagulants with INR ≤1.7: Give alteplase 1
  • Oral anticoagulants with INR >1.7: Do NOT give - this is a contraindication
  • End-stage renal disease on hemodialysis with normal aPTT: Give alteplase 1

Cerebral Microbleeds on MRI

  • 1-10 microbleeds: Reasonable to give alteplase 1
  • >10 microbleeds: Uncertain - individualize decision

Absolute Contraindications

Timing

  • Symptom onset or last known well >4.5 hours 1
  • Wake-up stroke with last known well >4.5 hours (unless DWI-FLAIR mismatch protocol used) 1

Imaging

  • Any intracranial hemorrhage on CT/MRI 1
  • Extensive regions of clear hypoattenuation/frank hypodensity 1

Dosing Algorithm

Standard dose: 0.9 mg/kg 1

  • Maximum total dose: 90 mg
  • Give 10% as IV bolus over 1 minute
  • Give remaining 90% as IV infusion over 60 minutes

Critical caveat: A lower dose of 0.6 mg/kg was tested and found NOT equivalent to standard dosing - do not use reduced doses 1

Post-Treatment Monitoring

  • Monitor BP every 15 minutes for first 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours
  • Keep BP <180/105 mmHg for 24 hours 1
  • No antiplatelet or anticoagulant therapy for 24 hours unless compelling indication where withholding poses substantial risk 1
  • Monitor for orolingual angioedema (occurs in ~5% of patients)
  • Assess for symptomatic intracranial hemorrhage

Key Clinical Pitfalls

Time is brain: The benefit of alteplase decreases significantly with every 15-minute delay 1. Do not waste time on unnecessary testing or consultations in clearly eligible patients.

Don't exclude based on mild symptoms: Even patients with mild deficits in the 0-3 hour window should receive treatment - the evidence supports benefit across all severity levels 1.

Age is not a barrier: Patients >80 years benefit equally in the 0-3 hour window 1. Only the 3-4.5 hour window has the age ≤80 restriction.

Prior antiplatelet use is NOT a contraindication: Both single and dual antiplatelet therapy are acceptable - give the alteplase 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.